

Vascular Anomalies: State of the Art Diagnosis and Treatment 2013

Kristina W. Rosbe MD
Director, Pediatric Otolaryngology
Consultant, UCSF Vascular Anomalies &
Birthmark Center (BVAC)

Department of Otolaryngology-Head and Neck Surgery
University of California-San Francisco



**I have no financial
disclosures**



Objectives


- Be able to distinguish between hemangiomas and vascular malformations
- Become familiar with appropriate diagnostic imaging
- Understand multidisciplinary approach and roles for medical therapy, sclerotherapy, and surgical intervention
- Recognize that increased understanding of the genetics and biology of these lesions are leading to new potential medical therapies and new clinical trials



Common Misconceptions

- All vascular birthmarks are **not** “hemangiomas”
- All vascular malformations are **not** “AVMs”
- 50% of patients referred to the UCSF Vascular Anomalies Center carry an incorrect diagnosis






Diagnosis of Vascular Anomalies

- **More important**
 - *age of patient*
 - *physical examination*
 - *history (esp. birth/childhood/recent activity)*
- **Less important**
 - *Imaging*
 - *Biopsy*

Hemangioma



Natural History



- Period of most rapid growth is between 4-6 weeks
- 80% of growth is done by 3-4 months
- Proliferate over ~6-9 months
 - deep & segmental IH grow longer
- Slowly involute over years

Focal vs Segmental



Propranolol for IH

- **Risks/Side Effects**
 - Bradycardia
 - Hypotension
 - Hypoglycemia
 - Sleep disturbance
 - Hyperkalemia
 - Bronchospasm/exacerbation of asthma

UCSF Propranolol Protocol

Suspension is 4mg/ml

0.15mg/kg TID for 2 days

0.30mg/kg TID for 3 days

0.45 mg/kg TID for 3 days

0.60mg/kg TID is target dose

<6mo should be fed Q 4 h

hold dose for pulse<120



Consensus Statement

Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. *Pediatrics* 2013;131:128-40.



Vascular Anomalies: Classification Clinical and Cellular Differences

Vascular Malformation

- Malformed blood vessels
- Present at birth
- Commensurate growth
- F/M: 1/1
- nl endothelial turnover
- nl FGF
- No GLUT 1 staining



Venous Malformation



Venous Malformation: Imaging

discreet/scattered lesion

T1: intermediate signal

T2: high signal

enhancement:
homogeneous

- no flow voids

can involve muscle/bone

+ phleboliths



Venous Malformation: Therapy

- Observation/Education
- Compressive stocking
- ASA/Lovenox (LIC) (check D-dimers and fibrinogen)
- Laser
- Surgery
- Sclerotherapy
- Rapamycin (MTOR)

Lymphatic Malformation




Lymphatic Malformation


- **Classification Systems**
 - *Microcystic vs. Macro*
 - *DeSerres*
 - **Suprahyoid vs. infra**
 - **Uni vs. Bi**

Lymphatic Malformation: Imaging

- macro- vs. micro-cystic
- multiple cysts
- T1: low (water) signal, unless prior hemorrhage, Rx
- T2: high (water) signal
- fluid-fluid layers typical



Imaging



Lymphatic Malformation: Therapy


- Observation/Education
- Compressive stocking
- Manual lymphatic drainage
- Surgery
- Sclerotherapy
- Propranolol
- Sildenafil
- Rapamycin



Vascular Lesions: Known Genetic Markers

- Capillary and AVM
 - *RASA-1*
- Lymphatic Malformations
 - *VEGFR3*
- Venous Malformations
 - *TIE2/TEK*
- Hemangiomas of Infancy
 - *GLUT1*
- Hamartomas and AVM
 - *PTEN*


Pathways involved in vascular anomalies



Brouillard P, and Viskula M Hum. Mol. Genet. 2007;16:R140-R149

nioff Children's Hospital

© The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org



UCSF Benioff Children's Hospital

Summary

- Vascular anomalies classifications are useful for prognosis and treatment planning
- History and PE are most important elements for accurate diagnosis
- Education about the natural history of the lesion is important for the patient/family
- Imaging can be helpful to differentiate between LM and VM and determine tissue involved “tip of the iceberg”
- Patients with complex lesions benefit from a multidisciplinary approach in a Vascular Anomalies Center
- New clinical trials are available based on ongoing discoveries and identification of therapeutic targets



UCSF Birthmark and Vascular Anomalies Center 1991-2013

